EU regulators highlight SME/public sector role in new drug approvals

Larger firms may account for the vast majority (87%) of new medicines recommended for approval by the European Medicines Agency, but smaller firms, academia, public bodies and public/private partnerships (PPPs) are responsible for initiating the development of than 40% of these products.